T cell-based immunotherapies, including CAR-T cell therapies, have significantly advanced treatment options for lymphomas ...

Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to ...

Epkinly is a CD3xCD20 bispecific antibody green-lit for the treatment of relapsed/refractory diffuse large B-cell lymphoma ...

The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with ...

Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.

Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide (Revlimid) and ...

When I started receiving treatment for follicular lymphoma, I wasn’t sure what to expect regarding treatment — and a lot of ...

With a median follow-up of 14.1 months, adding tafasitamab to lenalidomide and rituximab reduced the risk of progression, ...

Long-term data from the pivotal phase 3 ELARA trial showed durable efficacy with tisagenlecleucel in high-risk follicular ...

Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per ...